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Objectives: A recent Premier study reported that despite hemostat use, uncon-
trolled bleeding is prevalent across surgery types (32%-68%).  Drawbacks of current 
hemostats include limitations with efficacy on first attempt and sub-optimal ease-
of-use; thus, better hemostats are needed.  A study was conducted to estimate the 
cost impact of a novel fibrin sealant patch (EVARREST™) versus standard of care 
(SoC) in soft tissue and hepatic surgical bleeding. MethOds: An economic model 
quantified 30-day cost impact of EVARREST from a U.S. hospital perspective.  Key 
resources, from four trials, included quantity of initial treatment, re-treatment, 
operating time, hospitalization, transfusion risk, amount transfused, and ventilator 
utilization.  SoC was composed of Surgicel (88% to 100% in soft tissue, 34% to 65% 
in hepatic tissue) and conventional methods (e.g., manual compression, thrombin). 
Transplant patients were excluded from analyses.  The surgical analysis included 
resources clinically related to the significant hemostasis benefit of EVARREST vs. 
control (i.e., initial and re-treatment, operating time, transfusion). A hospital analy-
sis included all resources collected. Published data on U.S. costs were applied to 
resource use. Sensitivity analyses were conducted on several variables including 
number of EVARREST products used. Results: The surgical base-case analysis 
predicted that EVARREST was cost saving vs. SoC by $59 per patient (sensitivity 
range: -$300 to $900).  The hospital analysis predicts further resource reduction 
with EVARREST with cost-savings of $2,789 per patient (sensitivity range: -$1,830 to 
-$3,338).  Results were most sensitive to the number of pads used.  Composite results 
were primarily driven by the large benefit achieved with EVARREST in severe soft-
tissue bleeding. cOnclusiOns: In problematic soft tissue and hepatic bleeding, 
EVARREST may result in important cost savings for hospitals, in addition to meeting 
an important unmet need. This analysis suggests EVARREST’s impact on hospital 
cost may depend on surgical bleeding type and number of pads used. Further study 
in additional populations may confirm findings.
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Objectives: The Harmonic® scalpel has demonstrated clinical and surgical ben-
efits as an effective and efficient alternative to traditional electrosurgery. However, 
ultrasonic devices incur higher device cost than electrosurgery. The aim of this study 
is to review the economic evidence comparing total procedural costs performed 
with ultrasonic devices to conventional techniques. MethOds: A comprehensive 
literature review was conducted to identify publications where ultrasonic energy 
devices were used in comparison with conventional surgical techniques for the 
period 2004-2014. No restriction on the surgical specialty was applied. Primary inclu-
sion criteria were: 1) randomized-controlled studies; 2) human studies; 3) total 
procedure cost was evaluated for economic impact. Articles were reviewed to collect 
direct and indirect cost information such as OR time, blood loss, hospital length of 
stay, resource and surgical consumables, as well as quality of life data. Results: For 
39 articles identified for full-text screening, 9 articles were evaluated based on the 
inclusion criteria. Therapeutic areas included breast, colon, and thyroid surgery. All 
economic studies considered total medical direct costs. Except for one article that 
showed ultrasonic devices to be more expensive and one that showed no economic 
difference, all other articles demonstrated that the higher cost of the Harmonic® 
device is offset by improved clinical outcomes and efficiency without an increase in 
surgical complications, especially in complicated procedures entailing considerable 
loss of blood or longer operative time. The average overall cost savings ranged from 
$85 to $400 USD per patient. Two studies estimated the incremental cost-effective 
ratio and both indicated the Harmonic® device to be superior compared to conven-
tional technique. cOnclusiOns: Ultrasonic devices shorten OR time and improve 
clinical outcomes in a variety of procedures investigated without an increase in 
complications, and thus can be considered as a cost effective alternative to con-
ventional surgical techniques.
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Objectives: Surgical bleeding remains prevalent and associated with substan-
tial burden. Such bleeding can be more difficult to manage in certain surgeries 
(e.g., liver). Hemostats with a fibrinogen, thrombin and patch component may be 
especially beneficial for problematic bleeding types; however, direct comparative 
data are limited. This study indirectly compared the hemostats EVARREST and 
TachoSil. MethOds: A structured literature search identified studies of fibrin 
sealants combined with use of a pad, patch, fleece or sponge, for surgical bleeding. 
The search was restricted to RCTs, 2000 onward, studies including standard of care 
(SoC) and time to hemostasis (TTH). EVARREST (4 trials) and TachoSil (6 trials) were 
identified as the comparators. Pair-wise meta-analyses were completed using a 
random-effects model for hemostat vs. SoC. An adjusted indirect comparison was 
conducted using Bucher methodology and ITC software (Wells, 2009) for calculat-
ing the mean difference (MD) in TTH between EVARREST and TachoSil with 95% 
confidence intervals (CI). Mean TTH was analysed as it is a well-accepted, recom-
mended measure. Typically, TTH measurements began at either 3 or 4 minutes. 
SoC was used as the ‘anchor’ to perform the indirect comparison and consisted 
of either conventional methods or topical hemostats. Indirect comparisons were 
completed for all surgery types and a liver surgery subgroup. Results: A total of 
894 patients were assessed. Across surgery types, the adjusted indirect comparison 
demonstrated EVARREST reduced mean TTH by 1.15 minutes compared to TachoSil 
(MD: -1.15; 95%CI: -3.29, 0.99), however, this difference was not statistically sig-
nificant. In the subgroup of liver surgical bleeding, EVARREST significantly reduced 
mean TTH by 2.73 minutes (MD: -2.73; 95%CI: -4.48, -0.981). cOnclusiOns: This 
analysis suggests EVARREST may provide better hemostasis than TachoSil, particu-
equipment costs ($495 list price of Revolve per use) and depreciated cost of centrifu-
gation ($10 per use). Annualized difference in costs was also estimated. Results: 
Base case assumed 100 AFGs per year (150mL of fat injected per case). Mean time to 
complete AFG was substantially faster using Revolve than centrifugation: 29.1 min-
utes versus 116.1 minutes (range: 25.1-32.0 versus 104.1-125.8 minutes, respectively). 
Mean volume of fat injected was greater for Revolve than centrifugation: 210.0mL 
versus 92.0mL (ranges: 179.0-241.2 versus 82.4-101.2mL, respectively). Consequently, 
rate of completing AFG was greater with Revolve than centrifugation: 5.2mL/min 
versus 1.3mL/min (range: 4.7-6.0 versus 1.2-1.4mL/min, respectively). Estimated 
cost savings for Revolve versus centrifugation was $2,075 per case and $207,476 per 
year. cOnclusiOns: As popularity of AFG increases, evaluating economic impact of 
AFG systems becomes essential. Based on current findings, Revolve system results in 
substantial OR time and cost savings compared to centrifugation.
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Objectives: The main purpose of this study was to link clinical and administra-
tive healthcare databases in order to assess the economic impact of implantable 
cardioverter defibrillator (ICD) with or without cardiac resynchronization pacing 
(CRT-D) in Lombardy, the most populated Italian region providing universal health-
care coverage for about 10 million inhabitants. MethOds: Data were extracted 
from: i) data warehouse DENALI, that organizes healthcare administrative databases 
concerning all subjects covered by Lombardy Health System (HS); ii) national ICD 
database. After linking DENALI and clinical information extracted from the ICD 
database, we identified patients with ICD and followed them from the date of the 
first implant to 12/31/2010, recording hospitalizations, drugs and outpatient claims. 
Direct healthcare costs were analysed from the perspective of the HS. We estimated 
mean annual per-capita costs after the first ICD implant: overall and stratified by 
indication (primary and secondary prevention) or type of implanted device (sin-
gle-chamber, dual-chamber and CRT-D). Results: During the period 2003-2010, 
12,525 subjects underwent a first ICD implant. Mean annual per-capita cost during 
follow-up was € 6,086 (95%CI: 5,970-6,211): 72.7% due to hospitalizations (€ 4,422), 
15.7% to pharmacological therapies (€ 957) and 11.6% to outpatient services (€ 706). 
No difference was observed between the mean annual expenditure for primary 
(€ 6,179; 95%CI: 6,001-6,353) and secondary (€ 5,996; 95%CI: 5,821-6,185) prevention. 
As for the type of implanted device, patients with CRT-D cost more than those with 
single-chamber or dual-chamber: respectively € 6,592 (95%CI: 6,376-6,847), € 5,728 
(95%CI: 5,541-5,972) and € 5,932(95%CI: 5,717-6,117). The difference was attributable 
to hospitalization expenses. cOnclusiOns: ICD use is growing and it is important 
to assess the efficacy and the burden of this therapy, given its economic implica-
tions. The combined use of clinical information from national ICD database and big 
administrative data could overcome the limitation of both data sources, leading to 
an improvement in the monitoring of ICD therapy.
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Objectives: Diabetes (DM) is rapidly growing in China, affecting > 114 million peo-
ple. Lipohypertrophy (LH) is a known, preventable complication amongst insulin-
injecting DM patients. This study demonstrates the economic and patient burden of 
LH in China. MethOds: An observational study was conducted among 401 insulin-
injecting adult patients with DM from 4 cities, 2 with and 2 without pen needle 
reimbursement (PNR). Demographics, medical history, direct and indirect costs, 
insurance and PNR status were collected via patient survey, followed by HbA1c tests 
and physical exam to assess LH. Results: LH was present in 52.9% of participants. 
Patients were an average of 59.6 (SD= 11.5) years old and took insulin 5.6 (SD= 4.6) 
years, averaging 33.0 (SD= 18.4) U/day. HbA1c was 8.2% (1.8) and 7.7% (1.5), respec-
tively, in those with and without LH (p= 0.003). LH was associated with higher daily 
insulin dose (38.1U vs 27.1U, p< 0.001) and cost (RMB 8.2 vs 5.8, p< 0.001). Those with 
LH averaged 2.3 (2.2) nodes, had higher frequency of PN reuse (median 13.0 vs 7.5, 
p= 0.003), and greater total 6-month direct costs (RMB 5506.9 vs 5258.0, p= 0.037). 
With 8.4 million insulin injectors in China, the estimated excess annual direct cost 
of LH is RMB 2.2 billion ($360 million). Average pain scores (0-10) were higher if LH 
was present (2.7 vs. 2.0, p= 0.021), if ≥ 3 nodes were present (3.8 vs. 2.3, p< 0.001), and if 
PNs were not reimbursed (2.8 vs. 1.7, p< 0.001). Patient satisfaction decreased as pres-
ence, number, and size of LH nodes increased (all p< 0.05). cOnclusiOns: Adverse 
effects and implications of LH reach over half of insulin-injecting patients in China. 
Assessing for LH and providing patient education on proper injection technique, 
including injection site rotation and reducing PN reuse, should be incorporated into 
routine DM management. Doing so may decrease this preventable complication, 
which may lessen LH-related economic and patient burdens.
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